Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Skye Bioscience, Inc. (SKYE) had Normalized Pre-Tax Income of $-11.10M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-11.10M |
|
-- |
|
-- |
|
$11.76M |
|
$-11.76M |
|
$0.66M |
|
$-11.10M |
|
|
Normalized Pre-Tax Income |
$-11.10M |
$-11.10M |
|
$-11.10M |
|
$-11.10M |
|
$-11.10M |
|
$-11.76M |
|
$-11.58M |
|
39.65M |
|
39.65M |
|
$-0.28 |
|
$-0.28 |
|
| Balance Sheet Financials | |
$63.03M |
|
$1.30M |
|
$1.77M |
|
$64.79M |
|
$5.32M |
|
-- |
|
$0.22M |
|
$5.54M |
|
$59.25M |
|
$59.25M |
|
$59.25M |
|
30.98M |
|
| Cash Flow Statement Financials | |
$-9.19M |
|
$-12.81M |
|
$0.00M |
|
$68.42M |
|
$46.42M |
|
$-21.99M |
|
$2.20M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
11.85 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-9.19M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-18.74% |
|
-18.74% |
|
-17.14% |
|
-18.74% |
|
$1.91 |
|
$-0.23 |
|
$-0.23 |
|